Johan joined Lundbeckfonden Ventures in 2010 as a senior partner. He is a director of Acacia Pharma, Enterome, Iconic Therapeutics and VHSquared. Previously he was a board member of Syntaxin (sold to Ipsen), Celladon, Ziarco (sold to Novartis), River Vision (sold to Horizon), Bonesupport, EQL Pharma and KaroBio. Before joining Lundbeckfonden Ventures, Johan was a co-founder and CEO of Sound Biotech and co-founder and Senior Vice President of Research as well as Business Development of Biovitrum (now SOBI). Prior to these positions he worked a decade in the pharmaceutical company Pharmacia in discovery and early development positions of increasing responsibility. Johan trained as a Physical Chemist at University of Lund, Sweden, Scripps Research Institute, La Jolla, California and Harvard Medical School, Boston, Massachusetts. He is an associate professor in Physical Chemistry at the University of Lund, Sweden.